NEW YORK (GenomeWeb News) – German firm Mosaiques Diagnostics and Therapeutics has inked a contract with the US Food and Drug Administration to collaborate on the discovery and validation of biomarkers for assessing drug toxicity.

Under the partnership, the FDA will provide information about drugs, expected toxicities, and animal studies. Mosaiques will contribute its proteome analysis expertise, particularly in sample preparation of urine and capillary electrophoresis coupled mass spectrometry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.